The Schain Research Team

Malin Almgren, Ph.D.

CEO

Dr Almgren holds a M.Sc. in Chemistry from Stockholm University and a Ph.D. in Medicine from Karolinska Institutet (KI). With over 20 years in medical research, she has deep knowledge in several fields including genetics, immunology, neuroscience, and oncology including clinical trials and collaborations with industry. As an Assistant Professor at KI, she focused on environmental impact on autoimmunity and neonatology.
In addition to her scientific experience, she has a second career in Finance, having held positions as Director for Strategic Partnerships at a Swedish asset manager with focus on sustainable investment, and most recently as financial advisor, supporting M&A transactions in the healthcare sector at Experia Corporate Finance Advisors AB.

Christina Jones, Ph.D.

Scientific Director and Data Protection Officer

Dr Jones has a Ph.D. in Developmental Biology from Monash University, Australia, and has worked as a postdoctoral researcher at Karolinska Institutet, Sweden, studying human kidney regeneration. Christina has experience in preclinical research, project management, commercialization, academia/industry/clinical partnerships and scientific writing.

Kelvin Kwok, Ph.D.

Senior Scientist

Dr Kwok studied Biochemistry at Oxford University and did his Ph.D. in Endocrinology at University of Hong Kong. He has also worked as a postdoctoral researcher at Karolinska Institutet focusing on metabolic diseases before joining Schain Research. He is experienced in pre-clinical and clinical research, data analytics and scientific writing.

Tina Jacob, Ph.D.

Senior Scientist

Dr Jacob holds a Ph.D. from Karolinska Institutet in Stockholm, Sweden. Before joining Schain Research she focused on dermatology, oncology, and diagnostic assays. She is experienced in pre-clinical research, data analytics, ethical applications, project management, and scientific writing.

Moyukh Chowdhury, MD, MPH.

Scientist

Dr Chowdhury has completed his MD from Southern Medical University, China and Masters in Public Health from Umeå University as a Swedish Institute Scholar. He has a diverse research experience from Global public health to Nordic RWE and Market access. He has been involved in evaluating several international public health interventions and multi-country epidemiological studies besides the clinical work.

Alice Åslund, Ph.D.

Scientist

Dr Åslund has a Ph.D. in Molecular Bioscience from Stockholm University, Sweden, where her work focused on Type 2 Diabetes and Obesity. She has experience in pre-clinical research, data analytics, ethical applications, project management, and scientific writing.

Maika Ramacciato, PharmD.

Research Associate

Maika Ramacciato holds a PharmD from Tor Vergata University in Rome, Italy. Before joining Schain Research, she worked as Study Coordinator and Site Manager in different therapeutic areas such as gastroenterology, oncology, and metabolic diseases. Maika has experience in early and late clinical trials, observational studies including monitoring, and trial coordination.

Ahmad Abbadi, MD

Scientist

Dr Abbadi holds an MD from Jordan University of Science and Technology and a Master’s in Medical Sciences in Public Health Epidemiology from Karolinska Institutet. He worked previously with academia, governmental and non-governmental organizations. He has experience in tobacco control, urological epidemiology, project management, clinical research, data analysis and scientific writing.

Victoria Wyckelsma, Ph.D.

Senior Scientist

Dr. Wyckelsma has a PhD in Physiology from Victoria University, Australia. Before joining Schain Research, she completed postdoctoral fellowships in Australia and at Karolinska Institutet in Stockholm, Sweden focusing on exercise and muscle physiology. Victoria is experienced in preclinical and clinical research, project management, scientific writing, ethics applications and data analytics.

Maria Wahlström

Finance and Administration Manager

Maria holds a degree in accounting economics and payroll management with long and broad experience with project, sales, and marketing management within several industries and brands.

Board of Directors

Frida Schain, Ph.D.

Founder and Chairman of the Board

Dr Schain has a M.Sc. in Molecular Biology from Lund University and a Ph.D. in Medicine, Hematology, from Karolinska Institutet, where she focused on molecular aspects of inflammation and lymphoma pathogenesis. Her broad experience ranges from academic research and early drug discovery to the medical device and pharmaceutical industry. Her pharmaceutical industry experience includes leadership roles in medical affairs, real-world evidence, epidemiology and commercial aspects of drug development. Most recently, she was a Global Director at Janssen, Johnson & Johnson, focusing on evidence generation from a market access and medical affairs perspective. In this role she was also a member of the global real-world evidence leadership team.

Malin Heyman

Board Member

Malin Heyman has more than 20 years of experience from financial services at SEB and Nasdaq as well as co-founder of a fintech company, Swimbird AB. Her roles have ranged from business development, sales to leadership as head of financial services and products. With extensive experience from strategic work, process development and digitalisation, Malin will bring significant value to the organisation as we continue to develop our capabilities and services in evidence generation and health data sciences.

Lars Johansson

Board Member

Lars Johansson brings 30 years of experience from the medtech and pharmaceutical industry, including 13 years as General Manager for J&J in the Nordics. Lars has a track record of being an extraordinary leader and his experience covers all strategic and operational aspects of bringing innovative treatments to patients.

Magnus Björkholm, MD, Ph.D.

Senior Professor of Medicine, Karolinska University Hospital and Karolinska Institutet

Professor Björkholm´s research is focused on clinical, experimental and epidemiological studies of malignant hematological diseases, with particular expertise in lymphoma, leukemia, myeloma and myeloproliferative neoplasms. He has authored more than 500 peer reviewed papers.